Drug Profile
Research programme: antifungals - Intercell AG
Latest Information Update: 09 Mar 2012
Price :
$50
*
At a glance
- Originator Intercell
- Class Monoclonal antibodies; Vaccines
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Aspergillosis; Candidiasis
Most Recent Events
- 21 Apr 2011 Discontinued - Preclinical for Aspergillosis in Austria (unspecified route)
- 21 Apr 2011 Discontinued - Preclinical for Candidiasis in Austria (unspecified route)
- 21 Apr 2008 Preclinical trials in Aspergillosis in Austria (unspecified route)